biostudies-literatureZhang XNature Science Foundation of ChinaNational High Technology Research and Development Program of ChinaNational Key Basic Research Program of ChinaPKU People’s Hospital Research and development Funding19https://www.ebi.ac.uk/biostudies/studies/S-EPMC5436452biostudies-literatureUnknown14AIM:The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide. METHODS:Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened thClinical proteomicsThe serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients.PMC5436452Nature Science Foundation of ChinaRD 2013-13No.2010CB912703No.2006AA02A409Wang QZhang XJi LLou XPaul SKWen BLiu SSun HHou GfalseThe serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients.AIM:The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide. METHODS:Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened th2017-01-01T00:00:00Z20172025-04-04T08:13:00.308Z2019-03-27T02:45:18ZS-EPMC54364522852946610.1186/s12014-017-9154-0